Trial Profile

A Phase 1 dose escalation study of CND261

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 26 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CND 261 (Primary)
Indications Cancer; Rheumatoid arthritis
Focus Adverse reactions

Most Recent Events

20 Jun 2025 According to a Candid Therapeutics media release, Additional clinical data from this study expected in 2H of 2025.
13 Sep 2024 New trial record
09 Sep 2024 According to a Candid Therapeutics media release, company has completed Phase 1 dose escalation studies for CND106 and CND261 drug candidates.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com